Alliance for Cancer Gene Therapy, Inc. (ACGT) funds breakthrough research that is transforming cancer treatment through cell and gene therapy. This ACGT grant award is for those conducting translational cell and gene therapy research specifically in solid tumor cancers. Cell and gene therapy for solid tumors poses major challenges driven by antigen heterogeneity, physical exclusion, immunosuppressive microenvironments, genomic… Read more »
Alliance for Cancer Gene Therapy, Inc. (ACGT) funds breakthrough research that is transforming cancer treatment through cell and gene therapy. This ACGT grant award is for those conducting translational cell and gene therapy research specifically in solid tumor cancers. Cell and gene therapy for solid tumors poses major challenges driven by antigen heterogeneity, physical exclusion, immunosuppressive microenvironments, genomic… Read more »
ACGT announces the RFA for the 2025 Investigator Award of $500,000 for high impact, translational research in cell and gene therapies to treat gynecological cancers. Gyencological Cancers The ACGT RFA is specifically targeted to advance cell and gene therapy approaches to treating patients with gynecological cancers. – According to the latest American Cancer Society data,… Read more »
ACGT announces the RFA for the 2025 Investigator Award of $500,000 for high impact, translational research in cell and gene therapies to treat gynecological cancers. Gyencological Cancers The ACGT RFA is specifically targeted to advance cell and gene therapy approaches to treating patients with gynecological cancers. – According to the latest American Cancer Society data,… Read more »
With success in overcoming blood cancers using curative cell and gene therapies well established, Alliance for Cancer Gene Therapy’s current funding priority is focused on the most difficult-to-treat solid tumor cancers — including pancreatic cancer. Pancreatic cancer is an aggressive disease that is predicted to become the second leading cause of cancer-related death worldwide… Read more »